Results 1 to 10 of about 16,573 (210)

Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis [PDF]

JACC: Advances
Background: The ONCO DVT study revealed that 12-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (IDDVT) was superior to 3-month edoxaban treatment.
Tomoyuki Nagai, MD, Naohiko Nakanishi, MD, Yugo Yamashita, MD, Takeshi Morimoto, MPH, MD, Nao Muraoka, MD, Michihisa Umetsu, MD, Yuji Nishimoto, MD, Takuma Takada, MD, Yoshito Ogihara, MD, Tatsuya Nishikawa, MD, Nobutaka Ikeda, MD, Kazunori Otsui, MD, Daisuke Sueta, MD, Yukari Tsubata, MD, Masaaki Shoji, MD, Ayumi Shikama, MD, Yutaka Hosoi, MD, Yasuhiro Tanabe, MD, Ryuki Chatani, MD, Kengo Tsukahara, MD, Kitae Kim, MD, Satoshi Ikeda, MD, Takeshi Kimura, MD, Satoaki Matoba, MD   +23 more
doaj   +2 more sources

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication) [PDF]

Thrombosis Journal, 2019
Background This study involved a sensory evaluation of edoxaban orally disintegrating (OD) tablets in patients with nonvalvular atrial fibrillation who had been receiving the existing edoxaban film-coated tablets before the study.
Takeshi Yamashita, Joji Hagii, Yoshiyuki Morishima, Takaaki Akasaka, Takuyuki Matsumoto, Tetsuya Kimura   +5 more
doaj   +2 more sources

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor [PDF]

Drugs, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Henri Bounameaux, Alan J Camm
exaly   +3 more sources

Response to ‘Re: Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials’ [PDF]

, 2014
We estimated and compared the risk of clinically identified acquired drug resistance under immediate initiation [the currently recommended antiretroviral therapy (ART) initiation strategy], initiation with CD4 cell count less than 500 cells/μl and ...
Stavros K. Kakkos, George Kirkilesis, Ioannis A. Tsolakis   +2 more
openalex   +5 more sources

Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism [PDF]

Thrombosis Journal
Background Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence.
Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa   +20 more
doaj   +2 more sources

Prevalence, risk characteristics, and prediction of low-dose edoxaban treatment in hospitalized patients: a multicenter, observational cohort study [PDF]

Frontiers in Pharmacology
BackgroundTreatment with a low-dose non-vitamin K antagonist oral anticoagulant (NOAC) is common among hospitalized patients, and a model to predict the need for such treatment would support individualized interventions.
Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni, Wenxing Peng, Xiaoyu Li, Fen Li, Boya Chen, Haixia Cai, Yinping Liu, Song Du   +10 more
doaj   +2 more sources

Edoxaban versus Warfarin in Patients with Atrial Fibrillation [PDF]

New England Journal of Medicine, 2013
Robert P Giugliano, Eugene Braunwald, Michael D Ezekowitz   +2 more
exaly   +2 more sources

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism

Therapeutics and Clinical Risk Management, 2016
Katie B Tellor, Joseph S Van Tuyl, Anastasia L Armbruster Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, USA Abstract: Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in
Tellor KB, Van Tuyl JS, Armbruster AL
doaj   +3 more sources

Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers [PDF]

Frontiers in Pharmacology
PurposePregabalin, gabapentin, and carbamazepine, a potent inducer of cytochrome P450 (CYP) 3A4 and P-glycoprotein, are frequently used antiepileptic drugs that are often administered together with factor Xa inhibitors (FXaI).
Alexander Lenard, Simon A. Hermann, Felicitas Stoll, Juergen Burhenne, Kathrin I. Foerster, David Czock, Gerd Mikus, Andreas D. Meid, Walter E. Haefeli, Antje Blank   +9 more
doaj   +2 more sources

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial [PDF]

Journal of the American Heart Association, 2018
Robert P Giugliano
exaly   +2 more sources